Related Experiment Video
Updated: Apr 16, 2026
Multi-exon Skipping Using Cocktail Antisense Oligonucleotides in the Canine X-linked Muscular Dystrophy
Published on: May 24, 2016
Antisense-mediated exon skipping: a therapeutic strategy for titin-based dilated cardiomyopathy
Michael Gramlich1, Luna Simona Pane2, Qifeng Zhou3
1Department of Cardiology and Cardiovascular Diseases, Eberhard Karls University, Tübingen, Germany Victor Chang Cardiac Research Institute, Darlinghurst, NSW, Australia michael.gramlich@med.uni-tuebingen.de amoretti@med1.med.tum.de.
Insights
Antisense oligonucleotides can correct gene defects causing inherited dilated cardiomyopathy (DCM). This RNA-based therapy shows promise for treating DCM by restoring normal heart muscle function.
Area of Science:
- Genetics
- Cardiology
- Molecular Biology
Background:
- Frameshift mutations in the TTN gene are a primary cause of inherited dilated cardiomyopathy (DCM).
- Current DCM treatments are limited, with heart transplantation being the only definitive option.
- Titin (TTN) is crucial for myofibril assembly and cardiac function.
Purpose of the Study:
- To investigate the therapeutic potential of antisense oligonucleotide (AON)-mediated exon skipping for DCM caused by TTN frameshift mutations.
- To assess the efficacy of restoring the TTN reading frame in patient-derived cells and animal models.
Main Methods:
- Utilized patient-specific induced pluripotent stem cell-derived cardiomyocytes (iPSCCMs) and TTN knock-in mouse models.
- Employed antisense oligonucleotide (AON)-mediated exon skipping to correct the TTN reading frame.
- Evaluated myofibril assembly, sarcomeric protein expression, and cardiac contractile function.
Main Results:
- Correction of the TTN reading frame in iPSCCMs rescued myofibril defects and normalized sarcomeric protein expression.
- AON treatment in TTN knock-in mice improved sarcomere formation and contractile performance in homozygous embryos.
- Heterozygous TTN knock-in mice treated with AONs showed prevention of the DCM phenotype.
Conclusions:
- RNA-based strategies, specifically AON-mediated exon skipping, can restore the TTN reading frame disrupted by DCM-causing mutations.
- This approach demonstrates therapeutic potential for DCM patients by improving cardiac structure and function.
- Exon skipping offers a promising avenue for developing novel treatments for inherited dilated cardiomyopathy.
Abstract:
Frameshift mutations in the TTN gene encoding titin are a major cause for inherited forms of dilated cardiomyopathy (DCM), a heart disease characterized by ventricular dilatation, systolic dysfunction, and progressive heart failure. To date, there are no specific treatment options for DCM patients but heart transplantation. Here, we show the beneficial potential of reframing titin transcripts by antisense oligonucleotide (AON)-mediated exon skipping in human and murine models of DCM carrying a previously identified autosomal-dominant frameshift mutation in titin exon 326. Correction of TTN reading frame in patient-specific cardiomyocytes derived from induced pluripotent stem cells rescued defective myofibril assembly and stability and normalized the sarcomeric protein expression. AON treatment in Ttn knock-in mice improved sarcomere formation and contractile performance in homozygous embryos and prevented the development of the DCM phenotype in heterozygous animals. These results demonstrate that disruption of the titin reading frame due to a truncating DCM mutation can be restored by exon skipping in both patient cardiomyocytes in vitro and mouse heart in vivo, indicating RNA-based strategies as a potential treatment option for DCM.
